Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is a Schedule IV controlled substance.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initial dose:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week based on clinical response and tolerability.
* **Maintenance dose:** Typically 10-20 mg twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 years and older)
* **Initial dose:** 5 mg once daily.
* **Titration:** Increase dose by 2.5-5 mg every week based on clinical response and tolerability.
* **Maintenance dose:** Typically 10 mg twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day).
* *Note: Dosing may vary based on weight. Consult specific pediatric guidelines.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment provided, but consider reduced dosage and increased monitoring.
* **Renal Impairment:** Use with caution. No specific dose adjustment provided, but consider reduced dosage and increased monitoring.
* **Concomitant Medications:** Dose reduction may be necessary when coadministered with strong CYP3A4 inhibitors.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, dizziness, fatigue, drooling, constipation, decreased appetite, aggression, abnormal behavior, respiratory tract infections.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other benzodiazepines, sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam concentrations.
* **Stimulants (e.g., amphetamines):** May reduce the efficacy of clobazam.
## Monitoring
* Monitor for therapeutic efficacy and emergence of adverse effects, particularly somnolence and behavioral changes.
* Monitor for signs of suicidal behavior or ideation.
* Assess for signs of withdrawal upon discontinuation.
## Clinical Pearls
* Clobazam is generally initiated at a low dose and titrated slowly to minimize adverse effects.
* Due to the risk of somnolence, patients should be cautioned about driving or operating heavy machinery.
* Abrupt discontinuation can lead to withdrawal symptoms. Tapering is recommended.
* Clobazam is a significant CYP2C19 inhibitor; coadministration with substrates of this enzyme may require dose adjustments.
***
**Disclaimer:** This information is intended for healthcare professionals. It is not exhaustive and does not replace professional medical advice. Always verify current prescribing information and consult with relevant resources before making any clinical decisions. Dosing may vary based on local protocols and individual patient factors.
